ESR1 and metastatic neoplasm: Endocrine therapies, targeting ER directly or the production of excess estrogen, are commonly used in the adjuvant setting for ER-positive early-stage breast cancer and for the treatment of advanced or metastatic disease in combination with other targeted therapies (3).